Abstract
Background: Congenital thrombotic thrombocytopenic purpura (cTTP) is an extremely rare disease caused by an inherited deficiency of ADAMTS13. Residual ADAMTS13 activity ADAMTS13 gene. Daily fresh frozen plasma (FFP) infusions normalized platelet counts and hemolysis indices. Prophylactic plasma infusions were scheduled every 21 days. Despite prophylaxis, the child experienced multiple disease relapses after infectious episodes, requiring hospitalization and daily plasma infusions, sometimes complicated by infection or thrombosis related to venous access. Following ethics committee approval, recombinant ADAMTS13 was administered at 40 IU/kg every two weeks. After one year of treatment, the child experienced no disease recurrence and no infusion-related adverse events. No anti-ADAMTS13 antibodies were detected. Discussion: cTTP is a very rare disease, often misdiagnosed, with high neonatal mortality. Children frequently experience recurrent TTP triggered by infections. Prophylactic ADAMTS13 replacement should be considered to reduce disease recurrence. Recombinant ADAMTS13 appears to be a promising, effective, and safe therapeutic option.
Funding Information
  • Italian Ministry of Health
  • Italian Ministry of Education and Research—MUR

This publication has 18 references indexed in Scilit: